Inside the research
Thermo Fisher Scientific Inc.
TMO Research profile · latest available data
Price overview
$675.00
▼ -3.39 (-0.5%)
| 52w hi | $678.39 |
|---|---|
| 52w lo | $437.57 |
| Vol | 2.10M |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.43
| Short | +0.40 |
|---|---|
| Medium | +0.54 |
| Long | +0.26 |
computed 2026-09-27
Key fundamentals
Thermo Fisher Scientific Inc.
Healthcare · Diagnostics & Research
| Market cap | $249.58B |
|---|---|
| Enterprise value | $288.19B |
| Trailing P/E | 36.37x |
| Forward P/E | 24.51x |
| EV / EBITDA | 24.55x |
| P / S (ttm) | 5.39x |
| Profit margin | 15.0% |
| Return on equity | 13.5% |
| Revenue growth | +10.5% |
| Earnings growth | +9.4% |
| Debt / equity | 80.58 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.19 | |
| Sector | +0.08 | |
| Technical | +0.31 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Risk Metrics
| Beta vs SPX | 0.79 |
|---|---|
| Corr SPX | 0.41 |
| Annual vol | 30.6% |
| Annual ret | +9.4% |
| Sharpe | 0.31 |
| Max DD | -37.0% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $620.12 |
|---|---|
| High / Low | $750.00 / $520.00 |
| Median | $620.00 |
| Analysts | 24 |
| Strong Buy | 5 | |
|---|---|---|
| Buy | 19 | |
| Hold | 2 | |
| Sell | 0 | |
| Strong Sell | 0 |
Recent rating actions
| 2026-05-08 | Wells Fargo | → Overweight |
| 2026-04-24 | Stifel | → Buy |
| 2026-04-24 | Baird | → Outperform |
| 2026-04-14 | Barclays | → Overweight |
| 2026-04-06 | Evercore ISI Group | → Outperform |
| 2026-01-30 | TD Cowen | → Buy |
Officers & Board
| Director | R. Alexandra Keith since 2020 |
|---|---|
| Director | Debora Spar since 2019 |
| Director | James Mullen since 2018 |
| Director | Dion Weisler since 2017 |
| Director | Lars Rebien Sørensen since 2016 |
| Director | C. Martin Harris since 2012 |
| Director | Ruby Chandy since 2010 |
| Director | Nelson Chai since 2010 |
| Director | Marc N. Casper since 2009 |
| Director | Tyler Jacks since 2009 |
| Director | Scott Sperling since 2006 |
| Director | Jim Manzi since 2000 |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-07-23 | Earnings Release, Exhibits | read |
| 2026-05-26 | Shareholder Vote | read |
| 2026-04-23 | Earnings Release, Exhibits | read |
| 2026-03-24 | Other Material Event, Exhibits | read |
| 2026-02-12 | Material Agreement, Other Material Event… | read |
| 2026-01-29 | Earnings Release, Exhibits | read |
| 2026-01-12 | Officer / Director Change | read |
| 2025-12-01 | Material Agreement, Other Material Event… | read |
| 2025-10-29 | Other Material Event, Exhibits | read |
| 2025-10-22 | Earnings Release, Exhibits | read |
| 2025-10-07 | Material Agreement, Other Material Event… | read |
| 2025-09-02 | Other Material Event, Exhibits | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-11 | Shafer Michael D | Executive Vice President | Option exercise | 11.20K | $3.47M |
| 2026-08-11 | Shafer Michael D | Executive Vice President | Sell | 11.20K | $6.72M |
| 2026-08-11 | Shafer Michael D | Executive Vice President | Option exercise | 14.30K | $5.98M |
| 2026-08-11 | Shafer Michael D | Executive Vice President | Sell | 14.30K | $8.58M |
| 2026-08-07 | Holmes Joseph R. | VP & Chief Accounting Off | Option exercise | 420 | $130.04K |
| 2026-08-07 | Holmes Joseph R. | VP & Chief Accounting Off | Sell | 420 | $245.62K |
| 2026-08-07 | CASPER MARC N | Chairman & CEO | Option exercise | 275 | $85.15K |
| 2026-08-07 | CASPER MARC N | Chairman & CEO | Sell | 6 | $3.46K |
| 2026-08-07 | CASPER MARC N | Chairman & CEO | Sell | 4 | $2.32K |
| 2026-08-07 | CASPER MARC N | Chairman & CEO | Sell | 2 | $1.16K |
Flow & Concentration
| Insider 180d net | -$39.11M |
|---|---|
| Insider buys / sells | 0 / 69 |
| Insider bias | Sellers |
| 13F holders | 8 |
| Top-5 share | 99.2% |
| HHI | 3,963 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| State Street Corp | $8.44B | 16.83M |
| Fidelity / FMR LLC | $7.06B | 14.08M |
| Capital Research / Capital World | $1.29B | 2.57M |
| Citadel Advisors | $565.38M | 1.13M |
| Millennium Management | $129.39M | 258.07K |
| AQR Capital Management | $128.99M | 257.91K |
| Bridgewater Associates | $6.49M | 12.95K |
| T. Rowe Price Group | $2.57M | 5.12M |
As of 2026-06-30
Dividends
| Yield (TTM) | 0.13% |
|---|---|
| $ / share (TTM) | $0.90 |
| 5y CAGR | +14.3% |
Annual dividend per share
| 2021 | $1.04 |
|---|---|
| 2022 | $1.20 |
| 2023 | $1.40 |
| 2024 | $1.56 |
| 2025 | $1.72 |
| 2026 | $0.47 |
Federal Contracts
| Amount | Agency | Description |
|---|---|---|
| $26.00M | Department of Justice | ADDITIONAL FUNDS FOR OPTION YEAR TWO. |
| $21.47M | Department of Justice | FUNDING DOCUMENT FOR OY3. CONSUMABLES AND REAGENTS. |
| $21.24M | Department of Justice | ADDITIONAL OY1 FUNDING DOCUMENT. |
| $14.79M | Department of Justice | OY1 DELIVERY ORDER FOR LIFE TECHNOLOGIES REAGENTS AND CONSUMABLES. |
| $9.80M | Department of Justice | ADDITIONAL FUNDING DOCUMENT FOR OPTION YEAR THREE. (OB3) |
| $8.51M | General Services Administration | JPEO CBRND PROCUREMENT FOR FTIR AND RAMAN DEVICES |
| $8.13M | Department of Justice | OPTION YEAR TWO FUNDING DOCUMENT. |
| $3.35M | Department of Health and Human Services | LAB EQUIPMENT MAINTENANCE AGREEMENT |
SEC Filings
The Long Run
FY 2009–2025 · 17 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $42.86B | +9.7% | |
| Gross profit | $2.62B | +11.4% | |
| Operating income | $7.34B | +12.9% | |
| Net income | $6.00B | +51.6% | |
| Cash from ops | $8.67B | +11.7% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $677.53 | $678.00 | $664.53 | $675.00 | 2.10M |
| Sep 24 | $660.91 | $682.98 | $655.95 | $678.39 | 2.10M |
| Sep 23 | $657.61 | $671.47 | $655.78 | $665.30 | 2.35M |
| Sep 22 | $656.41 | $662.87 | $651.54 | $658.52 | 2.10M |
| Sep 21 | $653.89 | $660.44 | $649.12 | $658.76 | 2.30M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →